V Meisinger

Medical University of Vienna, Wien, Vienna, Austria

Are you V Meisinger?

Claim your profile

Publications (21)168.14 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Metal-on-metal articulations were reintroduced to reduce polyethylene particle-induced osteolysis. Elevated serum metal levels have been detected at short- and intermediate-term follow-up. There is little knowledge about long-term effects of increased ionic metal generation. Our study was undertaken to provide information about long-term survival, clinical outcome, radiographic appearance, and serum metal concentrations after a minimum 10 years follow-up with a metal-on-metal hip prosthesis: 105 cementless primary total hip prostheses with metal-on-metal articulating surfaces were implanted in 98 patients with a mean age of 56 years. Clinical data, radiographs, and blood samples were obtained at a follow-up visit 10 years after implantation. Serum cobalt and chromium levels were determined with use of atomic absorption spectrometry. General laboratory analyses included a full blood count and kidney function parameters. The Harris score was 92 points and the UCLA score 6 points after 10 years. Small osteolytic lesions and radiolucent lines were found in Gruen's zones 1, 7, 8, and 14. The probability of survival was 98.6%. The median serum cobalt concentration of the 22 patients with their hip replacement as the only source of cobalt was 0.75 microg/L (range, 0.3-50.1 microg/L). No patient was diagnosed with renal insufficiency during the study period. Five patients were diagnosed with a malignancy between surgery and the follow-up. We do not have evidence of an increased rate of primary malignancies nor could we detect renal failure in our study group. Serum metal levels did not differ from short- and intermediate term follow-up values.
    Journal of Orthopaedic Research 07/2007; 25(7):841-8. DOI:10.1002/jor.20381 · 2.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In a randomised study, 28 patients with a mean age of 62.2 years (32 to 81) with osteoarthritis or avascular necrosis of the hip received either a ceramic-on-ceramic or a metal-on-metal total hip replacement. Apart from the liners the acetabular and femoral components were made of Ti-Al-Nb alloy. The serum aluminium and cobalt levels were measured before, and at one year after surgery. The 15 patients in the ceramic-on-ceramic group had a median pre-operative aluminium level of 1.3 microg/l (0.25 to 8.4) and a cobalt level below the detection limit. At one year the aluminium level was 1.1 microg/l (0.25 to 2.3) and the cobalt level was 0.4 microg/l (0.15 to 0.7). The 13 patients in the metal-on-metal group had a median pre-operative aluminium level of 1.9 microg/l (0.25 to 4.4) and a cobalt level below the detection limit. At one year the median aluminium level was 0.9 microg/l (0.25 to 3.9) whereas the cobalt level was 1.4 microg/l (0.5 to 10.5). This increase in the cobalt level at one year was significant (p < 0.001). Our findings indicate that ceramic-on-ceramic bearings do not cause elevated levels of serum aluminium in the first post-operative year.
    The Bone & Joint Journal 08/2006; 88(8):1003-5. DOI:10.1302/0301-620X.88B8.17870 · 2.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Umbilical cord serum and corresponding maternal serum of 3 women with uncemented metal-on-metal total hip arthroplasties were analyzed for cobalt and chromium. The women were an average 3.8 (range, 2-5) years after hip surgery. At the time of delivery, the maternal chromium concentrations were 1.6 microg/l, 0.5 microg/l, and 0.9 microg/l, respectively, and the maternal cobalt concentration was 1 microg/l in the first woman and below the detection limit in the other 2 women. Cobalt and chromium concentrations of the 3 umbilical cord sera also were below the detection limit. This indicates that-with regard to the detection limit of our laboratory-we were unable to observe a passage of cobalt and chromium ions from metal-on-metal articulations across the placenta at the time of delivery.
    The Journal of Arthroplasty 01/2005; 19(8 Suppl 3):102-6. DOI:10.1016/j.arth.2004.09.020 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We investigated whether cup inclination influences serum levels of cobalt and chromium after metal-on-metal total hip arthroplasty. Out of a consecutive series, 3 groups of 20 patients each were established according to their cup inclination: greatest inclination (55 degrees -63 degrees, mean 58 degrees), intermediate inclination (44 degrees -46 degrees, mean 45 degrees), and smallest inclination (23 degrees -37 degrees, mean 33 degrees). We did not detect any statistically significant difference of serum cobalt (P = .23) or serum chromium (P = .13) levels between the 3 groups applying the Kruskal Wallis test. However, 3 patients with cup inclinations of 58 degrees , 63 degrees , and 61 degrees exhibited 9.8-53.6-fold elevated cobalt and 9.5-30.5-fold elevated chromium levels when compared with the median concentrations of this trial. We therefore recommend accurate cup placement also for metal-on-metal articulations.
    The Journal of Arthroplasty 01/2005; 19(8 Suppl 3):66-70. DOI:10.1016/j.arth.2004.09.003 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Systemic cobalt dissemination from the Metasul Co-28Cr-6Mo-0.2C metal-on-metal total hip prosthesis has been demonstrated in the first year after implantation. The aim of this prospective study was to monitor the serum cobalt concentrations in patients during the first five years after total hip arthroplasty with a metal-on-metal articulation. A total hip arthroplasty was performed without cement in 100 consecutive patients who had either unilateral osteoarthritis or unilateral osteonecrosis. Fifty patients were randomized to be treated with a metal-on-metal articulation, and fifty patients, with a ceramic-on-polyethylene bearing. The femoral stem was made of a Ti-6Al-7Nb alloy, and the threaded acetabular cup was made of commercially pure titanium. Blood samples were taken before the operation and at multiple time-points for five years after the operation. Serum cobalt concentrations were measured with use of atomic absorption spectrometry. In the metal-on-metal group, the median serum cobalt concentration was 1 micro g/L at one year after surgery and 0.7 micro g/L at five years. The median of the serum cobalt concentrations measured from three to twelve months did not differ from the median of subsequent measurements, with the numbers available. The median serum cobalt level in the control group of patients treated with the ceramic-on-polyethylene articulation was below the detection limit at all time-points. Systemic cobalt release from Metasul metal-on-metal articulations was demonstrated throughout the five-year study period. The median serum cobalt concentrations were found to be slightly above the detection limit and remained in a constant range. The serum cobalt concentrations did not reflect a so-called run-in wear period of the metal-on-metal articulations.
    The Journal of Bone and Joint Surgery 12/2003; 85-A(11):2168-73. · 4.31 Impact Factor
  • Zeitschrift für Orthopädie 01/2000; 138(5):425-429. DOI:10.1055/s-2000-10172 · 0.86 Impact Factor
  • S Wenger, V Meisinger, T Brücke, L Deecke
    European Neurology 02/1998; 39(3):187-8. · 1.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We determined serum cobalt levels in 55 patients by atomic absorption spectrophotometry before and after implantation of uncemented total hip arthroplasties. In a randomised, prospective trial 27 wrought Co-28Cr-6Mo-0.2C metal-on-metal articulations were compared with 28 ceramic-on-polyethylene hips which did not contain cobalt. Other sources of iatrogenic cobalt loading were excluded. The metal-on-metal group produced detectable serum cobalt levels (median 1.1 microg/l after one year) which were significantly different (p < 0.0001) from those of the ceramic-on-polyethylene control group (median below detection limit of 0.3 microg/l after one year). Our findings indicate that metal-on-metal bearings generate some systemic release of cobalt.
    The Bone & Joint Journal 03/1997; 79(2):316-21. DOI:10.1302/0301-620X.79B2.7326 · 2.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine if low-level exposure to lead has an effect on arterial blood pressure, demographic and clinical data of a group of 507 males without any occupational exposure to lead were analyzed in a retrospective study. The following variables were included in the analysis: age, height, weight, nicotine consumption, alcohol intake, blood lead, systolic blood pressure, diastolic blood pressure, and erythrocyte count. The effects of the variables age, weight, height, alcohol intake, nicotine consumption, and blood lead on blood pressure were investigated by stepwise linear regression analysis. The diastolic as well as the systolic blood pressure was significantly influenced by Body Mass Index, age, and alcohol. A significant effect of lead could be found only for diastolic blood pressure. None of the possible interactions were significant enough to merit inclusion in the statistical model. Regarding the strength of the effects on diastolic blood pressure we find that lead ranks after age, weight. In conclusion, this study shows that lead has an effect on diastolic arterial blood pressure in a survey of a group of middle-aged, occupationally nonexposed men.
    American Journal of Industrial Medicine 06/1995; 27(6):897-903. DOI:10.1002/ajim.4700270613 · 1.59 Impact Factor
  • B. Plöckinger, Ch. Dadak, V. Meisinger
    [Show abstract] [Hide abstract]
    ABSTRACT: Ohne Zusammenfassung
    Archives of Gynecology and Obstetrics 11/1993; 254(1):1588-1589. DOI:10.1007/BF02266544 · 1.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Serum ferritin levels, cumulative number of administered blood transfusions, number of monthly transfused blood units and total months on hemodialysis (HD) treatment differed significantly in 7 patients on hemodialysis with clinical, biochemical and histological evidence of hemosiderosis, when compared to 37 controls (p less than 0.001 for all parameters). As a new treatment method desferrioxamine (DFO) therapy was introduced for iron detoxification in these hemosiderotic chronically hemodialyzed patients. Hence, to maximize the biological half-time, 30 mg/kg body weight DFO were given after the end of HD in the iron-loaded patients. Iron removal during the subsequent HD and the increase of iron excretion by the stool after DFO was measured by atomic absorption spectroscopy. Iron removal by the artificial kidney was calculated by investigating the function (QDi + QF)CDo over the duration of HD treatment, which equals the total amount of iron removal during HD. Using numerical integration of measured data this removal was found to be 21.8 +/- 6.9 mg whereas cumulative iron loss via the feces was found to be 36.5 +/- 14.6 mg. Therefore, total iron elimination was calculated to be on average 50-60 mg after administration of a single dose of DFO. Furthermore, long-term treatment of 5 patients resulted in a significant decrease of serum ferritin levels from 2,309 +/- 295 to 715 +/- 177 ng WHO/ml (p less than 0.001) after a period of 36 +/- 5 months. We conclude, that DFO in a dosage of 30 mg/kg body weight given at the end of HD is able to remove more than 500 mg iron/month if it is administered following each HD. Long-term results indicate negative iron balance without significant change of transfusion frequency if not more than 2 U of blood (500 mg iron) are administered within 1 month. This treatment schedule might be superior compared to the previously used methods of administration where DFO was given at the beginning or throughout HD.
    Contributions to nephrology 02/1985; 49:44-55. · 1.53 Impact Factor
  • H K Stummvoll, H Graf, V Meisinger
    [Show abstract] [Hide abstract]
    ABSTRACT: The effects of desferrioxamine administration on aluminum kinetics during hemodialysis were studied. Desferrioxamine leads to an increase of plasma aluminum levels in patients on chronic hemodialysis which could be attributed to mobilization of tissue aluminum. The in vivo protein binding of aluminum was found to be 70% after administration of desferrioxamine vs. 80% without a premedication with desferrioxamine, thus greatly enhancing the concentration gradient between free diffusible plasma aluminum and dialysate aluminum. Desferrioxamine therefore leads to increased aluminum removal during hemodialysis and should be considered in the therapy of aluminum toxicity syndromes.
    Mineral and Electrolyte Metabolism 02/1984; 10(4):263-6.
  • H Graf, H K Stummvoll, Vanee Meisinger
    The Lancet 02/1982; 1(8262):46-7. DOI:10.1016/S0140-6736(82)92588-0 · 39.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aluminum kinetics were studied in 24 patients on chronic hemodialysis. All patients had elevated predialytic serum concentrations of aluminum (mean, 3.44 mumoles/liter), which correlated significantly with the ingestion of aluminum hydroxide (P less than 0.01). Simultaneous measurements of aluminum in plasma and ultrafiltrate revealed an ultrafiltrability of about 20% of total plasma aluminum, thus suggesting that 80% of aluminum is protein bound. When a dialysate with a very low aluminum content (varying from 0.1 to 0.3 mumoles/liter) was used, mean values across the dialyzer were 3.20 and 2.67 mumoles/liter, respectively, showing a significant decrease of plasma aluminum during dialyzer passage (P less than 0.0001). It could be shown that dialysance of aluminum depends on the concentration gradient between the free diffusible plasma aluminum and the dialysate aluminum concentration. After 6 hours of dialysis, plasma aluminum concentrations were significantly lower than were predialysis values (P less than 0.0001). We conclude that a negative aluminum balance during hemodialysis can be assumed as long as the aluminum concentration of free diffusible plasma aluminum lies above the aluminum concentration of the dialysate.
    Kidney International 05/1981; 19(4):587-92. DOI:10.1038/ki.1981.56 · 8.52 Impact Factor
  • H Graf, H K Stummvoll, V Meisinger
    [Show abstract] [Hide abstract]
    ABSTRACT: The effects of desferrioxamine administration of aluminium kinetics during haemodialysis were studied. Desferrioxamine leads to an increase of plasma aluminium levels in patients on chronic haemodialysis which could be attributed to mobilisation of tissue aluminium. Furthermore the ultrafiltrable function of plasma aluminium was greatly enhanced thus increasing the effective concentration gradient of aluminium between plasma and dialysate. Desferrioxamine therefore leads to increased aluminium removal during haemodialysis and should be considered in the therapy of aluminium toxicity syndromes.
    Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association 02/1981; 18:674-80.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aluminium kinetics in patients with endstage renal failure and chronic intermittent haemodialysis have been studied. All patients revealed elevated predialytic serum aluminum levels. Because of a significant correlation between daily intake of aluminiumhydroxyd and serum aluminium levels it is concluded that the intestinal aluminium absorption plays an etiological role in the development of hyperaluminaemia. Plasma aluminium levels at the end of a regular dialysis procedure are significant lower compared to predialytic values. Similarly a significant decrease of aluminium concentration was observed in the plasma after passage through the dialyzer. This is due to the fact that the aluminium content of the dialysate used in our unit (0.1-0.3 mumol/l) is lower than the ultrafiltrable fraction of the plasma aluminium measured in vivo. Therefore a negative aluminium-balance during haemodialysis has to be assumed in our patients. Extreme aluminium-accummulation seems to be avoided and we therefore never experienced aluminium intoxication and dialysis dementia in our center. To assess a negative aluminium balance during haemodialysis, because of high protein binding of aluminium, a dialysate with an extreme low aluminium content has to be recommended.
    Wiener klinische Wochenschrift 02/1980; 92(11):391-4. · 0.79 Impact Factor
  • Annals of internal medicine 02/1980; 92(1):130-1. · 16.10 Impact Factor
  • The Lancet 03/1979; 1(8112):379. · 39.21 Impact Factor
  • The Lancet 02/1979; 313(8112):379. DOI:10.1016/S0140-6736(79)92916-7 · 39.21 Impact Factor
  • B Plöckinger, C Dadak, V Meisinger
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the present study was to determine the toxic trace element status of 51 healthy Austrian women and their newborn babies. Lead, mercury and cadmium content of early breast milk, blood and urine were measured post partum by atomic absorption spectrophotometry. None of the toxic trace elements could be found in elevated concentrations; the content of mercury and cadmium in milk was below limits of detection. Mean lead concentration in breast milk was 35.8 (SD:15.0) micrograms/l. Whole blood content of lead was 37.0 (SD:12.7) micrograms/l in mothers and 26.3 (SD:11.6) in newborns. High blood concentrations of mercury were found both in mothers (4.46 micrograms/l, SD:1.95) and in umbilical cord blood (5.58 micrograms/l, SD:2.33). The corresponding values for cadmium were 0.44 (SD:0.4) micrograms/l and 0.08 (SD:0.16) micrograms/l. Urine excretion of the elements assayed was normal. Significant correlations between maternal and neonatal blood toxic mineral levels could be demonstrated in lead (p < 0.001).
    Zeitschrift für Geburtshilfe und Perinatologie 197(2):104-7.

Publication Stats

726 Citations
168.14 Total Impact Points


  • 2006–2007
    • Medical University of Vienna
      • Department of Orthopaedics
      Wien, Vienna, Austria
  • 2003–2005
    • Vienna General Hospital
      Wien, Vienna, Austria
  • 1979–1997
    • University of Vienna
      • Department of Internal Medicine III
      Wien, Vienna, Austria